If you have type 1 diabetes, you may have heard people talk about the iLet Bionic Pancreas and wondered, “When will the iLet Bionic Pancreas be available?” The good news is that you do not have to wait for a future launch—the iLet Bionic Pancreas is already an FDA-cleared automated insulin delivery system in the United States.
However, there is an important difference between FDA clearance, commercial availability, and the availability of a particular updated version. Recent regulatory developments involving Beta Bionics also make it especially important to check the current status of the device before making treatment decisions.
This guide explains what the iLet Bionic Pancreas is, when it became available, how it works, who it is designed for, and what patients should know about its current status.
The iLet Bionic Pancreas is already available in the United States. The U.S. Food and Drug Administration (FDA) cleared the iLet ACE Pump and iLet Dosing Decision Software in May 2023 for people ages 6 and older with type 1 diabetes. The system works with a compatible continuous glucose monitor (CGM).
Therefore, if you are searching for “when will the iLet Bionic Pancreas be available,” the answer is: it is not simply an upcoming product waiting for its initial U.S. launch—it has already reached the U.S. market.
That said, availability can depend on prescription requirements, insurance coverage, supplier inventory, compatible CGM systems, and the patient’s healthcare provider.
The iLet Bionic Pancreas is an automated insulin delivery (AID) system developed by Beta Bionics.
Unlike a traditional insulin pump that requires users or clinicians to program many insulin-delivery settings, the iLet system is designed to automate much of the insulin-dosing process.
The FDA describes the system as consisting of the iLet ACE Pump, iLet Dosing Decision Software, and a compatible integrated continuous glucose monitor. The software uses glucose information and other inputs to determine insulin delivery.
The goal is simple: reduce some of the daily burden associated with managing type 1 diabetes.
For many people living with diabetes, that can be meaningful. Diabetes management can involve countless decisions throughout the day, from monitoring glucose to calculating insulin doses. Automated technology is intended to make some of those decisions easier.
The FDA announced clearance of the iLet ACE Pump and iLet Dosing Decision Software on May 19, 2023.
The clearance applies to people 6 years of age and older with type 1 diabetes. The system uses an algorithm to determine and command insulin delivery based on CGM information and meal announcements.
The FDA’s database also records the 510(k) clearance for the iLet ACE Pump in 2023.
This means patients who meet the appropriate criteria have not needed to wait for a hypothetical future FDA approval of the original iLet system.
The confusion is understandable.
Diabetes technology changes quickly. Companies frequently introduce:
As a result, someone may hear about a new iLet-related announcement and assume that the entire iLet system has not yet been released.
There can also be differences between FDA clearance and actually obtaining a device. A device may be legally marketed while an individual patient still needs a prescription, insurance authorization, training, or assistance from a healthcare provider.
The iLet Bionic Pancreas is designed to work as an automated insulin delivery system.
A compatible CGM provides glucose information. The iLet system then uses its dosing software to help determine insulin delivery.
One of the system’s distinctive features is its approach to meal announcements. Rather than requiring the user to calculate an exact carbohydrate amount for every meal, the system allows users to identify a meal as relatively small, medium, or large. The algorithm then uses that information together with glucose data to determine insulin delivery.
This does not mean the device completely eliminates diabetes management. Users still need to interact with the system, monitor their health, follow their healthcare team’s instructions, and respond appropriately to alerts or other situations.
No.
The FDA’s 2023 clearance was for people 6 years and older with type 1 diabetes.
That distinction matters.
People with type 2 diabetes, gestational diabetes, or other forms of diabetes should not assume that an FDA-cleared indication for type 1 diabetes automatically applies to them.
If you are considering an automated insulin delivery system, discuss your individual situation with your endocrinologist or diabetes care team.
Because this article addresses current availability, it is important to mention recent regulatory developments rather than relying only on older information.
In January 2026, the FDA issued a warning letter to Beta Bionics following an inspection. The FDA’s letter addressed issues involving the company’s quality systems, medical-device reporting, and corrective/removal procedures.
The FDA also identified concerns involving an iLet software correction/removal and reporting requirements.
These developments do not mean that the original answer to “when will the iLet Bionic Pancreas be available?” changes to “it is not available.” The iLet had already been cleared and commercialized.
However, they do mean that patients, caregivers, healthcare professionals, and suppliers should pay attention to official safety communications, device updates, and manufacturer instructions.
The FDA’s medical-device recall database lists a Class II recall associated with the iLet Bionic Pancreas, posted April 29, 2026.
A recall does not automatically mean every device in use must be discarded. The specific recall information, affected product or lot, corrective action, and instructions should be reviewed carefully.
If you currently use an iLet system, do not make changes to your insulin therapy simply because you read about a recall online. Instead, review the official notice and contact your diabetes care team or the appropriate manufacturer support channel for instructions.
Not necessarily.
This is an important distinction.
Medical-device recalls can involve specific products, configurations, software, lots, or corrective actions. A recall is different from saying that an entire product category has permanently disappeared from the market.
The FDA database currently identifies an iLet Bionic Pancreas recall, so consumers should verify whether their particular device is affected.
For current availability, patients should check with their healthcare provider, authorized suppliers, and the manufacturer rather than relying on an old article or social-media post.
The iLet platform continues to evolve.
For example, Beta Bionics has expanded compatibility with newer CGM technology, including the Dexcom G7 platform. This illustrates why “availability” can mean different things depending on whether someone is asking about the original iLet system or a newer combination of pump, software, and CGM technology.
For patients, the most useful question may therefore be:
“Which iLet system and compatible CGM options are currently available and appropriate for me?”
That is a much more practical question than simply asking whether the iLet exists.
Automated insulin delivery can potentially reduce some of the mental workload involved in diabetes management.
Potential advantages may include:
However, benefits vary from person to person.
An automated system is not a cure for diabetes, and it does not guarantee perfect glucose control.
If you are thinking about the iLet, consider more than simply whether it is available.
The FDA clearance is specifically for people 6 years and older with type 1 diabetes.
Eligibility can depend on age and the applicable indication.
The pump is intended to work with a compatible integrated CGM. Make sure you understand which CGM options are currently supported.
Even when a device is FDA-cleared, insurance coverage can vary.
Talk with your healthcare provider about whether the iLet is appropriate for your treatment plan and how to obtain it.
Automated insulin delivery is still medical therapy. Understanding alarms, supplies, CGM readings, infusion-set management, and troubleshooting is important.
Because regulatory and recall information can change, always check current official information rather than relying on older online articles.
The iLet is a prescription medical device, so people should not treat it like an ordinary consumer electronics product.
Your healthcare provider can determine whether it is appropriate for you and help with the prescription and setup process.
A medical equipment supplier can also help patients understand product availability and supply options, but the decision to use an insulin-delivery system should be made with appropriate medical guidance.
This is where it becomes especially important to distinguish between the iLet Bionic Pancreas already available today and future Beta Bionics products.
Beta Bionics has also been developing other diabetes technology. For example, the company announced expectations to commercialize its Mint patch pump by the end of the second quarter of 2027, subject to FDA clearance.
That product should not be confused with the currently marketed iLet Bionic Pancreas.
In other words:
iLet Bionic Pancreas = already FDA-cleared and available.
Future Beta Bionics products = may have different regulatory and commercialization timelines.
If you are looking for diabetes supplies, it is helpful to work with a medical supply company that understands the difference between glucose-monitoring products, insulin-delivery equipment, and other durable medical equipment.
Alfa Healthcare Supply Inc. provides medical equipment and healthcare supplies and can be a resource for patients looking for diabetes-related medical supplies.
Availability of a particular insulin pump or CGM can change, so patients should confirm current inventory, prescription requirements, insurance eligibility, and product compatibility before ordering.
If you came here searching “when will the iLet Bionic Pancreas be available,” the most important thing to know is that the wait for the original U.S. launch is already over.
The FDA cleared the iLet system in 2023, and it has been commercialized as an automated insulin delivery option for eligible people with type 1 diabetes.
At the same time, diabetes technology does not stand still. New CGMs, software updates, regulatory actions, recalls, and next-generation devices can change the practical availability of specific configurations.
As of 2026, consumers should therefore look beyond the simple question of whether the iLet exists. The better question is whether the currently available iLet system is appropriate for your diabetes care, compatible with your CGM, available through your supplier, covered by your insurance, and suitable according to your healthcare provider.
For anyone considering an automated insulin delivery system, that conversation with a qualified diabetes care professional is an important step. The right technology should not only be available—it should also be appropriate for the person using it.
The iLet Bionic Pancreas is already available in the United States. The FDA cleared the iLet ACE Pump and iLet Dosing Decision Software in May 2023 for people age 6 and older with type 1 diabetes.
The FDA cleared the iLet ACE Pump and iLet Dosing Decision Software through the 510(k) pathway. The system is used with a compatible FDA-cleared integrated CGM.
The FDA’s clearance includes people 6 years of age and older with type 1 diabetes.
The term “bionic pancreas” is used for the system because it automates insulin delivery based on glucose information and other inputs. However, it does not completely replace the biological functions of a healthy human pancreas.
Yes. The iLet Bionic Pancreas is designed to work with a compatible integrated continuous glucose monitor.
The system was designed to reduce the need for precise carbohydrate calculations. Users can announce meals using meal-size categories, while the dosing algorithm determines insulin delivery.
The iLet has already been commercialized. However, current product availability, affected devices, recalls, software updates, and compatible CGM options should be confirmed through current official sources and your healthcare provider.
Yes. The FDA recall database lists a Class II recall associated with the iLet Bionic Pancreas, posted April 29, 2026.
Do not make changes to insulin therapy based solely on an online article. Check the official recall information to determine whether your device is affected and follow instructions from your healthcare provider and the manufacturer.